Once-daily AZILECT^® is well tolerated.

Incidence of side effects in monotherapy similar to placebo.^1,2

• Low discontinuation rate due to adverse events with AZILECT^® as monotherapy (5% vs 2% for placebo).²
• Patients have been treated with AZILECT^® for up to 5 years in clinical trials. The long-term safety profile was similar to that observed with shorter duration exposure.²

Most common adverse events as monotherapy.*

Incidence of side effects in adjunct therapy.*

• The most common adverse reactions for patients on AZILECT^® as adjunct therapy were dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, ecchymosis, somnolence, and paresthesia. None of these occurred in >18% of patients.²

Can be administered with other PD therapies.²

• In adjunct therapy trials, approximately 65% of patients were also taking a dopamine agonist, and in the PRESTO trial 35% were also taking entacapone. The majority of patients taking entacapone were taking a dopamine agonist as well.²

*Incidence >5% of patients on AZILECT^® (monothearpy and the 1 mg group in adjunct trials) and at least 1.5x the incidence in the placebo group. As monotherapy, headache was the most frequently reported adverse event.

1. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol. 2002;59(12):1937-1943.
2. AZILECT^® Prescribing Information.

06282390/061150